Ritzman sells Rx business to CVS PharmacyCVS Pharmacy is set to acquire 20 of Ritzman Pharmacy's retail pharmacies by the end of February. Alembic gets approval for 2 genericsThe FDA has approved Alembic's generic Mirapex and Patanol, which had a market value of roughly $38.6 million, and $61 million, respectively. Pliaglis’ ‘Not for Home Use’ label restriction gets green lighted Crescita's Pliaglis received approval from the Food and Drug Administration for removal of the "Not for Home Use" label restriction. Patient-facing pharmacies: Technology for enhanced engagement LexisNexis Risk Solutions' Craig Ford looks at how pharmacists play a key role in care delivery as patients can walk right up to the counter with a question without an appointment. Hy-Vee implements controlled substance prescription policy Hy-Vee's pharmacies are aiming to combat the opioid epidemic with a new controlled substance prescription policy. Braeburn's Brixadi gets tentative approval Braeburn's Brixadi offers treatment for patients with moderate-to-severe opioid use disorder. FDA approves new Sprycel indication The Food and Drug Administration has given Bristol-Myers Squibb approval for a new pediatric indication for Sprycel. Sanofi, Merck get Vaxelis approval Sanofi and Merck received the FDA's approval for a new vaccine that will not have a commerical supply available in the United States prior to 2020. Lupin, AbbVie partner to develop cancer drugs Lupin and AbbVie have formed a partnership to develop Lupin's MALT1 inhibitors. Hikma, Sciecure Pharma ink deal for niche injectable anti-viral medicines Hikma expects its deal with Sciecure will expand its pipeline of niche products. First Previous 511 512 513 514 515 Next Last
